makaluvamine L

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: makaluvamine L
• 英文别名: 10-[[(E)-2-(4-hydroxyphenyl)ethenyl]amino]-7-methyl-2-aza-7-azoniatricyclo[6.3.1.04,12]dodeca-1(11),2,4(12),7,9-pentaen-11-ol
• 化学式: C₁₉H₁₈N₃O₂
• 分子量: 320.371
• InChiKey: JDEIENKFJZZZCA-UHFFFAOYSA-O

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  24
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.16
• 拓扑面积：
  67.9
• 氢给体数：
  3
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  makaluvamine L 以 乙醇 为溶剂， 反应 8.0h， 以12.5%的产率得到(9CI)-1,3,4,5-四氢-5-甲基-吡咯并[4,3,2-de]喹啉-7,8-二酮
  参考文献：
  名称：

  UV-stability and UV-protective activity of alkaloids from the marine sponge Zyzzya fuliginosa

  摘要：

  研究了海洋海绵 Zyzzya fuliginosa 中的生物碱--达米龙 A (1) 和 B (2)；马卡卢瓦胺 H (3)、C (4)、G (5) 和 L (6)；以及zyzzyanones A (8) 和 B (9)--保护海胆 Strongylocentrotus nudus 的卵细胞膜免受紫外线辐射的能力。达米隆、zyzzyanones 和三环马卡卢胺 C (4) 和 H (3) 表现出最强的膜保护活性。研究表明，马卡鲁胺 G (5) 和 L (6) 在紫外线照射下分别转化为达米隆 A (1)、B (2)，三环马卡鲁胺 H (3)、C (4)，以及zyzzyanones A (8)和 B (9)。

  DOI：

  10.1007/s10600-006-0040-7

文献信息

• [EN] PYRROLOQUINOLIN COMPOUNDS AND METHODS OF USING SAME<br/>[FR] COMPOSÉS DE PYRROLOQUINOLÉINE ET LEURS MÉTHODES D'UTILISATION
  申请人：UNIV CALIFORNIA

  公开号：WO2018170019A1

  公开（公告）日：2018-09-20

  Provided are pyrroloquinolin compounds of formula (1) or (II). In certain aspects, the pyrroloquinolin compounds are therapeutic, e.g., for treating a cell proliferative disorder. Also provided are conjugates that include the pyrroloquinolin compounds of the present disclosure. Compositions, e.g., pharmaceutical compositions, that include the pyrroloquinolin compounds and conjugates of the present disclosure are also provided. Further provided are therapeutic methods involving the administration of the pyrroloquinolin compounds, conjugates or compositions of the present disclosure. Kits that include the pyrroloquinolin compounds, conjugates or compositions are also provided. Formula (I), (II).

  提供了式（I）或（II）的吡咯喹啉化合物。在某些方面，这些吡咯喹啉化合物具有治疗作用，例如用于治疗细胞增殖性疾病。还提供了包括本公开的吡咯喹啉化合物的结合物。还提供了包括本公开的吡咯喹啉化合物和结合物的组成物，例如制药组成物。还提供了涉及给予本公开的吡咯喹啉化合物、结合物或组成物的治疗方法。还提供了包括吡咯喹啉化合物、结合物或组成物的试剂盒。式（I），（II）。
• Pyrroloquinolin compounds and methods of using same
  申请人：The Regents of the University of California

  公开号：US11020488B2

  公开（公告）日：2021-06-01

  Provided are pyrroloquinolin compounds of formula (1) or (II). In certain aspects, the pyrroloquinolin compounds are therapeutic, e.g., for treating a cell proliferative disorder. Also provided are conjugates that include the pyrroloquinolin compounds of the present disclosure. Compositions, e.g., pharmaceutical compositions, that include the pyrroloquinolin compounds and conjugates of the present disclosure are also provided. Further provided are therapeutic methods involving the administration of the pyrroloquinolin compounds, conjugates or compositions of the present disclosure. Kits that include the pyrroloquinolin compounds, conjugates or compositions are also provided.

  所提供的是式(1)或(II)的吡咯喹啉化合物。在某些方面，这些吡咯喹啉化合物具有治疗作用，例如用于治疗细胞增殖性疾病。还提供了包括本公开的吡咯喹啉化合物的共轭物。还提供了包括本公开的吡咯喹啉化合物和共轭物的组合物，例如药物组合物。此外，还提供了涉及施用本公开的吡咯喹啉化合物、共轭物或组合物的治疗方法。还提供了包括吡咯喹啉化合物、共轭物或组合物的试剂盒。
• Zyzzyanones B−D, Dipyrroloquinones from the Marine Sponge <i>Zyzzya </i><i>f</i><i>uliginosa</i>
  作者：Natalia K. Utkina、Aleksandra E. Makarchenko、Vladimir A. Denisenko

  DOI：10.1021/np050154y

  日期：2005.9.1

  Zyzzyanones B, C, and D (2-4), three new dipyrroloquinones with a pyrrolo[3,2-f]indole-4,8(1H,7H)-dione skeleton, have been isolated from the Australian marine sponge Zyzzya fuliginosa. The known zyzzyanone A, makaluvamines C, E, G, H, and L, damirones A and B, 3,7-dimethylguanine, and 4-hydroxybenzoic acid were also isolated. The structures of the new compounds 2-4 were established by extensive NMR spectroscopic data. Compounds 2-4 showed moderate cytotoxic activity against mouse Ehrlich carcinoma cells (IC50 25 mu g/mL).
• PYRROLOQUINOLIN COMPOUNDS AND METHODS OF USING SAME
  申请人：The Regents of the University of California

  公开号：US20200129631A1

  公开（公告）日：2020-04-30

  Provided are pyrroloquinolin compounds of formula (1) or (II). In certain aspects, the pyrroloquinolin compounds are therapeutic, e.g., for treating a cell proliferative disorder. Also provided are conjugates that include the pyrroloquinolin compounds of the present disclosure. Compositions, e.g., pharmaceutical compositions, that include the pyrroloquinolin compounds and conjugates of the present disclosure are also provided. Further provided are therapeutic methods involving the administration of the pyrroloquinolin compounds, conjugates or compositions of the present disclosure. Kits that include the pyrroloquinolin compounds, conjugates or compositions are also provided.